Video Series

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.

The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib preferred for adolescents aged 12 to 17 and patients with baseline dyslipidemia, and deuruxolitinib reserved for those seeking faster and more robust hair regrowth or who have not responded adequately to another JAK inhibitor.

Dr. Mostaghimi discussed the clinical trial data for deuruxolitinib, a JAK1/2 inhibitor dosed at 8 mg twice daily, which demonstrated a faster onset of action compared with baricitinib and ritlecitinib — achieving mid-30% Scalp Area and Hair Loss Tool (SALT) score less than 20 response rates at 24 weeks, approximately 3 months earlier than baricitinib at 36 weeks.

The panelist examined the pivotal trial design for baricitinib, which enrolled patients with severe AA — defined as a Scalp Area and Hair Loss Tool (SALT) score greater than 50 — and demonstrated that approximately 30% of patients achieved a SALT score below 20 at 36 weeks on the 4 mg dose, with the 2 mg dose performing substantially lower.

Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA.

The expert clinician examined the multidisciplinary approach to alopecia areata care, with the board-certified dermatologist serving as the central coordinator, supported by pediatricians and family practice providers for early recognition and timely referral, dermatopathologists for cases requiring biopsy, and specialists in endocrinology, rheumatology, and psychiatry or psychology for management of associated comorbidities and psychosocial needs.

The panelist discussed the SALT scoring system, which divides the scalp into four regions — the frontal parietal scalp, bilateral preauricular and postauricular scalp, and posterior scalp — and evaluates the percentage of hair loss in each area to produce a composite score ranging from 0 to 100, with a score below 20 serving as the primary efficacy benchmark in JAK inhibitor clinical trials.

Dr. Amy McMichael highlighted the clinical presentation of alopecia areata, describing the characteristic patchy, round hair loss that can progress to more extensive forms including ophiasis, alopecia totalis, and alopecia universalis, with associated symptoms such as burning, stinging, conjunctivitis, and worsening allergic reactions from loss of eyelash and nasal hairs.

The panelists highlighted how stigma, misdiagnosis, and the concentration of mental health care in primary care settings collectively contribute to significant delays in patients receiving appropriate psychiatric treatment for MDD, bipolar depression, and schizophrenia.

Learn why CKD often goes undiagnosed in type 2 diabetes and how UACR screening plus obesity therapies can cut cardiovascular risk.

Uncover hidden CKD in type 2 diabetes: boost UACR screening, close diagnosis-to-treatment gaps, and navigate modern obesity therapies.

Factor XIa inhibitors emerge as safer stroke prevention, cutting harmful clots without excess bleeding—see which oral and IV drugs reach phase 3.

Learn how anticoagulants, antiplatelets, and atrial appendage closure prevent repeat ischemic stroke—and why early follow-up boosts adherence.

How awareness, screening, and team-based care help catch chronic kidney disease early and cut heart risk with new protective medicines.

Learn how tailored meds, diet, exercise, and cholesterol control help prevent repeat ischemic stroke—while balancing bleeding risk and adherence.

Experts reveal gaps in stroke detection, follow‑up and prevention, plus a simple “MATH” guide to hemorrhagic causes and blood pressure goals.

Seventy percent of participants rated total symptom clearance as very important—higher than any other treatment attribute, including speed of response or convenience. How does this align with what dermatologists have traditionally defined as treatment success?

Rising urine albumin signals higher heart and kidney risk; learn how better screening, EHR prompts, and new therapies can transform CKD care.

Discover the stroke care team—from primary care to rehab—plus proven prevention steps and the high stakes of recurrent stroke.

Stroke subtypes vary widely, but prevention is clear: control blood pressure, diabetes, cholesterol, exercise, quit smoking, and cut disability costs.

A retrospective analysis comparing 3-year psoriatic arthritis incidence across immunomodulatory classes finds an emerging signal favoring IL-23 pathway agents—a finding with meaningful implications for treatment selection in patients at risk for joint disease.

The panelist explored the following critical questions: What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments? What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care? What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions: The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Rising urine albumin signals hidden kidney and heart risk; learn why earlier UACR/eGFR screening and new therapies can change CKD outcomes.

An analysis of the POSITIVE study showed that tildrakizumab not only clears skin but substantially reduces itch, pain, and fatigue, with psychological well-being scores ultimately surpassing general population norms by year 2.